Why a BAFF CAR for Autoimmune Versus CD19 Targeting?

Time: 4:30 pm
day: Conference Day One


Developing a unique ligand-based CAR that targets three antigen receptors provides promising therapies for both oncology and autoimmune indications

Utilizing the BAFF CAR to identify and remove autoreactive B-cells by directly targeting the B-cell activating factor receptors, eliminating the cause of inflammation at the source